<DOC>
	<DOCNO>NCT02343172</DOCNO>
	<brief_summary>To determine MTD/RP2D HDM201 LEE011 combination evaluate whether combination safe beneficial effect patient liposarcoma .</brief_summary>
	<brief_title>Study Safety Efficacy HDM201 Combination With LEE011 Patients With Liposarcoma</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>Patients histologically document , locally advanced metastatic WD/DD liposarcoma receive least one prior systemic therapy Patients radiologic progression , define RECIST v.1.1 , occur on/or within 6 month last systemic treatment , prior enrollment ECOG performance status 01 Prior treatment compound mode action Patients TP53 mutate tumor , molecular status know Symptomatic central nervous system metastasis Inadequate organ function Previous concomitant therapy precludes enrollment , define protocol Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liposarcoma ,</keyword>
	<keyword>MDM2 inhibition ,</keyword>
	<keyword>cdk4 inhibition ,</keyword>
	<keyword>HDM201 ,</keyword>
	<keyword>LEE011</keyword>
</DOC>